Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Creso Pharma and Virbac launches hemp‐based animal feed product in Switzerland

Virbac is one of the top 10 veterinary pharmaceutical companies in the world.
a plant
Anibidiol is a natural complementary feed

Creso Pharma Ltd (ASX:CPH) and Virbac SA (EPA:VIRP) have launched Anibidiol®, a hemp‐based complementary animal feed product in Switzerland.

Anibidiol is a natural complementary feed for companion animals containing a standardised amount of hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant.

Creso has developed and will manufacture the product and Virbac will launch, market and promote it to veterinarians and pet owners.

Virbac is headquartered in France and is one of the top 10 veterinary pharmaceutical companies in the world.

Creso and Virbac had signed an agreement in September 2017, which will remain in effect for at least 3 years, in Switzerland and Lichtenstein.

Creso’s anibidiol®1.25 and anibidiol® 2.5 are designed for companion animals such as dogs and cats and come in proprietary granule formulations.

Anibidiol promotes the well-being of the animal by supporting its immunity and natural defence system. The product also supports the pet’s balanced behaviour.

The recession-resistant worldwide animal health market is valued at circa US$30 billion.

It is worth noting that 41% of pet owners have considered or tried various alternative therapies including nutritional supplements (29%) and herbal remedies (7%).

Creso’s share price increased circa 45% during the past one month, last closing at $0.80.

View full CPH profile View Profile

Related Articles

blood cells
October 23 2017
“We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020.”
PreveCeutical Medical bidding to be big player in preventive healthcare
October 10 2017
Van Deventer aims to grow the firm's valuation from its current $40mln market cap to $1bn plus in the next few years
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use